TREATMENT OF UPPER FACIAL LINES

Abstract: the present invention provides a modified bont/a for use in treating facial lines, wherein the modified bont/a is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified bont/a is administered by way of a unit dose of greater than 1754 pg (e.g. greater than 1800 pg) of modified bont/a per site, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines, and up to three sites of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified bont/a administered during the treatment is up to 88,000 pg, and wherein the modified bont/a comprises a bont/a light-chain and translocation domain (hdomain), and a bont/b receptor binding domain (hdomain).

Inventor(s): Nicolae Grigore, Laurent Pons, Katie Ruffle, Philippe Picaut

CPC Classification: A61K8/66 (Enzymes)

Search for rejections for patent application number 20250177278